151590-36-2 Usage
Uses
Used in Pharmaceutical and Medicinal Fields:
(E)-3-(6-methyl-1H-indol-3-yl)acrylic acid is used as a compound with potential therapeutic properties for its anticancer, antimicrobial, and anti-inflammatory activities. The presence of the indole group and carboxylic acid functional group in its structure allows for further chemical modifications to optimize its pharmaceutical applications.
Used in Drug Development:
(E)-3-(6-methyl-1H-indol-3-yl)acrylic acid is used as a starting material for the development of new drugs and therapeutic agents. Its unique structure and functional groups make it a promising candidate for the creation of novel pharmaceutical compounds with improved efficacy and reduced side effects.
Used in Chemical Modification:
(E)-3-(6-methyl-1H-indol-3-yl)acrylic acid is used as a building block for chemical modification, enabling the synthesis of new compounds with enhanced therapeutic properties. The acrylic acid moiety in the molecule provides opportunities for further functionalization and optimization of its biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 151590-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,1,5,9 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 151590-36:
(8*1)+(7*5)+(6*1)+(5*5)+(4*9)+(3*0)+(2*3)+(1*6)=122
122 % 10 = 2
So 151590-36-2 is a valid CAS Registry Number.
151590-36-2Relevant academic research and scientific papers
Discovery of a novel series of indolyl hydrazide derivatives as diacylglycerol acyltransferase-1 inhibitors
Kim, Minkyoung,Kwon, Jinsun,Kim, Mun Ock,Singh, Sarbjit,Kim, Sang Kyum,Lee, Kyeong,Lee, Kiho,Lee, Hyun Sun,Choi, Yongseok
, p. 628 - 635 (2015/05/04)
A novel series of hydrazide derivatives were synthesized as potential diacylglycerol acyltransferase (DGAT) inhibitors. Among them, compounds 8u and 8v exhibited selective and potent DGAT-1 inhibitory activities. In addition, compound 8u dose-dependently inhibited triglyceride synthesis in HepG2 cell lines. Furthermore, treatment with compound 8u for an oral lipid tolerance test showed a significant decrease in plasma triglyceride levels compared with vehicle-treated control animals, indicating delayed absorption of triglyceride after an acute lipid challenge.
